Galantamina para la enfermedad de Alzheimer y el deterioro cognitivo leve
Información
- DOI:
- https://doi.org/10.1002/14651858.CD001747.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 25 enero 2006see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Demencia y trastornos cognitivos
- Copyright:
-
- Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Clement Loy took over from Jason Olin as main reviewer for the updates of this review from November 2003. He dealt with article collection, in‐ and exclusion of new references, updated the data‐ analyses and rewrote the manuscript where necessary
Lon Schneider co‐wrote, reviewed article coding, and assisted with editing the manuscript, for the original review as well as all subsequent updates.
Consumer Editors: Enid Light and Mervyn Richardson
Contact Editor: Leon Flicker
Sources of support
Internal sources
-
No sources of support supplied
External sources
-
National Institute of Mental Health (MH01368 (OLIN), MH19074, MH48759), USA.
-
National Institute on Aging (AG05142), USA.
-
NIMH Clinical Antipsychotic Trials of Interventions Effectiveness, USA.
Declarations of interest
Dr. Schneider and the University of Southern California have received clinical trials‐and other contracts from Janssen Pharmaceutica and Johnson and Johnson, Inc. Dr. Schneider has served as a consultant to Janssen, Pfizer, and Novartis, all manufacturers of cholinesterase inhibitors used to treat AD, and to Forest Pharmaceuticals, manufacturer of memantine used to treat AD, for which he received payments. Dr. Loy has received a Wellcome Trust Travelling Award in relation to his work with the Cochrane Collaboration.
Acknowledgements
We gratefully acknowledge the contributions of Jason Olin who was the original main reviewer of this review and of Enid Light, the consumer editor.
Version history
| Published | Title | Stage | Authors | Version |
| 2006 Jan 25 | Galantamine for Alzheimer's disease and mild cognitive impairment | Review | Clement Loy, Lon Schneider | |
| 2004 Oct 18 | Galantamine for Alzheimer's disease | Review | Clement Loy, Lon Schneider | |
| 2002 Jul 22 | Galantamine for Alzheimer's disease | Review | Jason T Olin, Lon Schneider | |
Notes
August 2004:
A trial studying the efficacy of Galantamine in mixed Alzheimer's Disease/ vascular dementia was added.
Analyses for GAL‐INT‐2 and GAL‐93‐01 were amended based on press reports, slightly changing existing analyses, and adding additional data that was previously unavailable. Added references for publication of GAL‐INT‐1 and GAL‐93‐01.
Notes:
‐Tariot global rating formerly was stated as cibic‐plus. The citation for the was the ADCS‐CGIC. This has been corrected.
‐Raskind global rating formerly was stated as cibic‐plus. The citation for the was the ADCS‐CGIC. This has been corrected.
‐Rockwood global rating was formerly stated as cibic‐plus. The citation for the was the ADCS‐CGIC. This has been corrected.
‐Wilcock global rating was formerly stated as cibic‐plus. The citation for the was the ADCS‐CGIC. This has been corrected.
New data tables were added for 3‐month adverse events and discontinuations.
November 2005
Trials were added, studying the efficacy of Galantamine in Mild Cognitive Impairment, and the efficacy of Prolonged Release formulation of Galantamine in Alzheimer's Disease.
Death rates for the Galantamine trials were also recorded.
